Albavir 600mg Tab - Combination Of Abacavir & Lamivudine, Strength Of 600mg, Anti-viral Agents For Hiv Treatment, Supports Immune Function

ALBAVIR 600MG is a combination of Abacavir and Lamivudine which belongs to the group of medicines called Anti-viral agents. It is used in the treatment of HIV infection in adults, adolescents and in children (weighing above 25 kgs). HIV (human immunodeficiency virus) infection is a viral infection that damages our immune system and weakens our bodys ability to fight against various infections.

Both abacavir and lamivudine are nucleoside reverse transcriptase inhibitors. They work by blocking the actions of certain viral enzymes (HIV-reverse transcriptase) that is required for the viral cell to grow and multiply. This prevents further multiplication of viral cells within the body. Also, they can improve immunity in the affected patients by increasing the number of certain types of white blood cells (CD4) in the body which is required to fight against various infections.

ALBAVIR 600MG cannot not cure HIV infection completely. It can reduce only the number of viral cells present in the body and maintains them at a lower level. During treatment with ALBAVIR 600MG your doctor will closely monitor your body weight, blood cholesterol levels and blood sugar levels to reduce the risk of unwanted side effects.

Do not take ALBAVIR 600MG if you are allergic to abacavir or lamivudine. Before taking ALBAVIR 600MG inform your doctor if you have diabetes or any liver (hepatitis C or B infection), kidney or heart problems. If you are already taking ALBAVIR 600MG to treat hepatitis B or C infection, do not stop taking it without consulting your doctor.

Even if you take ALBAVIR 600MG, it is important for you to follow certain measures to prevent the spread of infections to the other people (such as avoid having unprotected sexual intercourse or sharing needles or personal items like toothbrush, razors etc with other people). ALBAVIR 600MG is not recommended for use in pregnant or breastfeeding women.